Thermo Fisher Scientific Files Q1 Report, Reveals $1.075B Microbiology Business Divestiture, and Details Recent Acquisitions
Summary
Thermo Fisher Scientific reported strong Q1 2026 financial results, announced a new $1.075 billion divestiture, provided details on a $9.1 billion acquisition, and disclosed additional restructuring plans.
Key Events
-
Strong Q1 2026 Financial Performance
Reported Q1 2026 revenues of $11.005 billion, a 6% increase from $10.364 billion in Q1 2025. GAAP diluted EPS grew 11% to $4.43, and adjusted EPS increased 6% to $5.44, reflecting solid operational execution.
-
Agreement to Divest Microbiology Business
Entered into an agreement on April 27, 2026, to sell its microbiology business to Astorg for approximately $1.075 billion, consisting of cash and a $50 million seller note. The sale is expected to close in the second half of 2026.
-
Completed $9.1 Billion Clario Holdings Acquisition
Finalized the acquisition of Clario Holdings, Inc. on March 24, 2026, for a total purchase price of $9.099 billion. This expands the Laboratory Products and Biopharma Services segment with clinical research offerings.
-
Significant Share Repurchases
Repurchased $3.00 billion of common stock (4.9 million shares) during Q1 2026 under the $5.00 billion authorization from November 2025, with $2.00 billion remaining for future repurchases.
Analysis
This quarterly report provides comprehensive financial results for Q1 2026, confirming strong performance with increased revenues and EPS. While headline Q1 figures were previously announced, this filing introduces new material information, notably the agreement to divest the microbiology business for $1.075 billion, a strategic move to optimize the company's portfolio. It also details the completed $9.099 billion acquisition of Clario Holdings and outlines additional restructuring charges of $290 million aimed at streamlining operations. The continued significant share repurchases further underscore management's commitment to shareholder returns. Investors should view the divestiture as a positive step towards strategic focus and the overall financial health as robust, despite the near-term restructuring costs.
At the time of this filing, TMO was trading at $472.21 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $175.5B. The 52-week trading range was $385.46 to $643.99. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.